Endocrine Department, Dubai Hospital, United Arab Emirates.
Diabetes Res Clin Pract. 2019 Apr;150:301-307. doi: 10.1016/j.diabres.2019.01.037. Epub 2019 Feb 12.
We aimed at evaluating the safety of fasting Ramadan for insulin treated type 2 diabetes patients by assessing the biochemical, biometric parameters, flash glucose monitoring (FGM) data as compared to pre-Ramadan and hospital admissions with diabetes or non-diabetes conditions. The risks of fasting between those treated with basal insulin vs intensive insulin during Ramadan was also assessed.
We included insulin treated patients with type 2 diabetes and we excluded those with co-morbidities. Patients were provided with Ramadan-focused education, FGM before and during Ramadan and medical advice for treatment adjustment. We measured biologic and biometric data before and after Ramadan.
HbA1c reduced from 7.9 ± 1.20 pre-Ramadan to 7.7 ± 1.5% post Ramadan (p = 0.023). Average peak glucose reading was 330.1 ± 79.8 mg/dl before Ramadan improved significantly to reach 289.3 ± 77.7 mg/dl (p = 0.013). Average number of hypoglycemic episodes was higher in intensive insulin group between 1200 and 1800 h (p = 0.028).
People with type 2 diabetes treated with insulin who fast Ramadan and who are provided with Ramadan focused patient education, individualized treatment adjustment and FGMS were not at increased safety risks as measured by biochemical, biometric and FGM data.
通过评估生化、人体测量参数和瞬感血糖监测（FGM）数据，比较斋月前后和糖尿病或非糖尿病住院期间的情况，评估接受胰岛素治疗的 2 型糖尿病患者在斋月期间禁食的安全性。还评估了在斋月期间接受基础胰岛素与强化胰岛素治疗的患者禁食的风险。
我们纳入了接受胰岛素治疗的 2 型糖尿病患者，并排除了患有合并症的患者。为患者提供了针对斋月的教育、斋月前后的 FGM 和治疗调整的医疗建议。我们在斋月前后测量了生物学和人体测量数据。
HbA1c 从斋月前的 7.9±1.20 降至斋月后的 7.7±1.5%（p=0.023）。平均峰值血糖读数在斋月前为 330.1±79.8mg/dl，显著改善至 289.3±77.7mg/dl（p=0.013）。在 1200 至 1800 小时之间，强化胰岛素组的低血糖发作次数较高（p=0.028）。
接受胰岛素治疗的 2 型糖尿病患者在斋月期间接受了针对斋月的患者教育、个体化治疗调整和 FGM，并通过生化、人体测量和 FGM 数据测量，没有增加安全性风险。
